

1. POMALYST [package insert]. Summit, NJ. Celgene Corp.
2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.
3. EMPLICITI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
4. Isatuximab-irfc [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC.
5. Rifkin RM, Durie BG-M, Gasparetto CJ, et al. Treatment patterns from 2009 to 2015 in patients with newly diagnosed multiple myeloma in the United States: a report from the Connect[®] MM registry. Poster presented at: 58th Annual Meeting of the American Society of Hematology; December 3-6, 2016; San Diego, CA.
6. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma in patients with ≥ 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. *Oncologist*. 2016;21(11):1355-1361.
7. Hajek R. Strategies for the treatment of multiple myeloma in 2013: moving toward the cure. In: Hajek R, ed. *Multiple Myeloma*. IntechOpen; 2013. doi:10.5772/55366.
8. REVLIMID [package insert]. Summit, NJ: Celgene Corp.
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Multiple Myeloma V.4.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed May 8, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
10. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. *Lancet Oncol*. 2013;14(11):1055-1066.
11. Data on file. Celgene Corporation.

12. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood*. 2017;130(8):974-981.
13. Dimopolous MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. *N Engl J Med*. 2018;379(19):1811-1822.
14. Shelat S. An open label, randomized phase 2 trial of pomalidomide/dexamethasone with or without elotuzumab in relapsed and refractory multiple myeloma (ELOQUENT-3). Clinical Protocol CA204125. Updated December 26, 2019. Accessed February 11, 2020. <https://clinicaltrials.gov/ct2/show/NCT02654132>.
15. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label phase 3 study. *Lancet*. 2019;394(10214):2096-2107.